UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 75

Sortiert nach

Correction: A scoping review of statistical methods in studies of biomarker-related treatment heterogeneity for breast cancer

BMC medical research methodology, 2023-09, Vol.23 (1), p.1-202, Article 202

2023

Volltextzugriff (PDF)

A scoping review of statistical methods in studies of biomarker-related treatment heterogeneity for breast cancer

BMC medical research methodology, 2023-06, Vol.23 (1), p.154-154, Article 154

2023

Volltextzugriff (PDF)

Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model

Cancer cell, 2003-09, Vol.4 (3), p.181-189

2003

Volltextzugriff (PDF)

Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study

European journal of cancer (1990), 2018-02, Vol.90, p.92-101

2018

Volltextzugriff (PDF)

Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study

Cancer, 2024-08, Vol.130 (16), p.2746-2762

2024

Volltextzugriff (PDF)

Abstract PD4-12: Clustering of activated proteins of the PI3K and MAPK pathways distinguishes ER+/HER2- primary breast cancer patients with preferential tamoxifen benefit

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.PD4-12-PD4-12

2018

Volltextzugriff (PDF)

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)

European journal of cancer (1990), 2018-10, Vol.102, p.40-48

2018

Volltextzugriff (PDF)

Abstract P1-13-10: Adjuvant treatment of HER2+ breast cancer: Should trastuzumab be given sequentially or concurrently with chemotherapy?

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-13-10

2018

Volltextzugriff (PDF)

Abstract P4-08-06: Phosphorylation of insulin-like growth factor-1 receptor (IGF-1R) is associated with tamoxifen resistance by activating the PI3K/MAPK pathway

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P4-P4-08-06

2018

Volltextzugriff (PDF)

Abstract P2-09-16: How population-based data complement trial data in the adjuvant endocrine treatment of ER+/HER2+ breast cancers

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P2-P2-09-16

2017

Volltextzugriff (PDF)

Abstract P4-21-30: Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-21-30

2017

Volltextzugriff (PDF)

Abstract OT1-01-08: Intensified alkylating chemotherapy in patients with oligo-metastatic breast cancer harboring homologous recombination deficiency: The OLIGO study

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT1-01-08-OT1-01-08

2017

Volltextzugriff (PDF)

Outside director compensation policy and the investment opportunity set

Journal of corporate finance (Amsterdam, Netherlands), 2005-09, Vol.11 (4), p.680-715

2005

Volltextzugriff (PDF)

Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors

Breast care (Basel, Switzerland), 2022-04, Vol.17 (2), p.208-223

2022

Volltextzugriff (PDF)

Abstract P1-06-07: Characterization of chromosomal instability in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P1-P1-06-07

2019

Volltextzugriff (PDF)

Abstract S6-06: The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat?

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.S6-S6-06

2016

Volltextzugriff (PDF)

Abstract PD5-02: The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat?

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.PD5-02-PD5-02

2016

Volltextzugriff (PDF)

Abstract OT1-03-10: A phase I followed by a r andomiz e d phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy v ersus capec i tabine in BRCA-1 or -2 mutated Her2 negative ad v anced breast c a ncer as first l ine treatment (REVIVAL study)

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.OT1-03-10-OT1-03-10

2016

Volltextzugriff (PDF)

Abstract P4-14-11: No impact of osteoporosis or bisphosphonate use for osteoporosis on breast cancer outcome: A sub-study of the DATA trial

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-14-11

2019

Volltextzugriff (PDF)

Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene

Oncogene, 2001-10, Vol.20 (45), p.6551-6558

2001

Volltextzugriff (PDF)

Abstract OT2-07-08: Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III trial

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.OT2-07-08-OT2-07-08

2018

Volltextzugriff (PDF)

Abstract P1-14-16: Weekly paclitaxel, trastuzumab, carboplatin is a highly effective neoadjuvant regimen in HER2-positive breast cancer: Results from the TRAIN-study

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P1-P1-14-16

2016

Volltextzugriff (PDF)

Abstract P3-07-28: BRCA1-like profile as predictive biomarker in non myeloablative chemotherapy (GAIN study)

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P3-P3-07-28

2016

Volltextzugriff (PDF)

Abstract S3-05: Higher 10-year overall survival after breast conserving therapy compared to mastectomy in early stage breast cancer: A population-based study with 37,207 patients

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.S3-S3-05

2016

Volltextzugriff (PDF)

Abstract P6-08-06: Neoadjuvant tamoxifen therapy synchronizes ERα binding and gene expression profiles

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P6-P6-08-06

2016

Volltextzugriff (PDF)

1 – 25 von 75

Suche als RSS-Feed

Aktive Filter

KollektionEBSCOhost Business Source Ultimate

Nur zeigenMit Volltextzugriff

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Publikationsform

Artikel
(74)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Life Sciences & Biomedicine
(30)
Humans
(20)
Biological And Medical Sciences
(14)
Female
(13)
Oncology
(12)
Breast Cancer
(11)
Adult
(10)
Business & Economics
(8)
Medical Sciences
(8)
Middle Aged
(8)
Social Sciences
(8)
Business, Finance
(7)
Economics
(7)
Animals
(6)
Fundamental And Applied Biological Sciences. Psychology
(6)
Northern America
(6)
U.S
(6)
Breast Neoplasms - Drug Therapy
(5)
Male
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Correction: A scoping review of statistical methods in studies of biomarker-related treatment heterogeneity for breast cancer

A scoping review of statistical methods in studies of biomarker-related treatment heterogeneity for breast cancer

Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model

Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study

Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study

Abstract PD4-12: Clustering of activated proteins of the PI3K and MAPK pathways distinguishes ER+/HER2- primary breast cancer patients with preferential tamoxifen benefit

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)

Abstract P1-13-10: Adjuvant treatment of HER2+ breast cancer: Should trastuzumab be given sequentially or concurrently with chemotherapy?

Abstract P4-08-06: Phosphorylation of insulin-like growth factor-1 receptor (IGF-1R) is associated with tamoxifen resistance by activating the PI3K/MAPK pathway

Abstract P2-09-16: How population-based data complement trial data in the adjuvant endocrine treatment of ER+/HER2+ breast cancers

Abstract P4-21-30: Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle

Abstract OT1-01-08: Intensified alkylating chemotherapy in patients with oligo-metastatic breast cancer harboring homologous recombination deficiency: The OLIGO study

Outside director compensation policy and the investment opportunity set

Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors

Abstract P1-06-07: Characterization of chromosomal instability in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

Abstract S6-06: The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat?

Abstract PD5-02: The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat?

Abstract OT1-03-10: A phase I followed by a r andomiz e d phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy v ersus capec i tabine in BRCA-1 or -2 mutated Her2 negative ad v anced breast c a ncer as first l ine treatment (REVIVAL study)

Abstract P4-14-11: No impact of osteoporosis or bisphosphonate use for osteoporosis on breast cancer outcome: A sub-study of the DATA trial

Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene

Abstract OT2-07-08: Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III trial

Abstract P1-14-16: Weekly paclitaxel, trastuzumab, carboplatin is a highly effective neoadjuvant regimen in HER2-positive breast cancer: Results from the TRAIN-study

Abstract P3-07-28: BRCA1-like profile as predictive biomarker in non myeloablative chemotherapy (GAIN study)

Abstract S3-05: Higher 10-year overall survival after breast conserving therapy compared to mastectomy in early stage breast cancer: A population-based study with 37,207 patients

Abstract P6-08-06: Neoadjuvant tamoxifen therapy synchronizes ERα binding and gene expression profiles

Aktive Filter

Suchergebnisse filtern